European Journal of Internal Medicine
Volume 20 , Pages S319-S328 , July 2009

Incretin Therapies: Effects Beyond Glycemic Control

  • Sunder Mudaliar, MD

      Affiliations

    • Section of Diabetes/Metabolism, VA San Diego HealthCare System, San Diego California, USA
    • Department of Medicine, University of California at San Diego, San Diego, California, USA
    • Corresponding Author InformationCorresponding author. Requests for reprints should be addressed to Sunder Mudaliar, MD, VA San Diego HealthCare System (Mail Code: 111G), 3350 La Jolla Village Drive, San Diego, California 92161.
    • ,
  • Robert R. Henry, MD

      Affiliations

    • Section of Diabetes/Metabolism, VA San Diego HealthCare System, San Diego California, USA
    • Department of Medicine, University of California at San Diego, San Diego, California, USA

  • Image Result

    Glycemic and extraglycemic effects of incretins/glucagonlike peptide–1 (GLP-1) agents. BP = blood pressure; CNS = central nervous system; GI = gastrointestinal.

    *Mediated centrally.

    Glycemic and extraglycemic effects of incretins/glucagonlike peptide–1 (GLP-1) agents. BP = blood pressure; CNS = central nervous system; GI = gastrointestinal.

    *Mediated centrally.

✩ This article is a copublication with the American Journal of Medicine, 122, S25-S36. For citation purposes please use European Journal of Internal Medicine, 20, S319-S328.

✩✩ Supported by the Department of Veteran Affairs. Dr. Mudaliar and Dr. Henry are employees of the Department of Veteran Affairs.

PII: S0953-6205(09)00097-1

doi: 10.1016/j.ejim.2009.05.010

European Journal of Internal Medicine
Volume 20 , Pages S319-S328 , July 2009

Article Tools

* Image Usage & Resolution